Literature DB >> 10590275

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

C Thornsberry1, M E Jones, M L Hickey, Y Mauriz, J Kahn, D F Sahm.   

Abstract

A national antimicrobial resistance surveillance study was conducted from December 1997 to May 1998 to determine the prevalence of antimicrobial resistance in 6620 clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. In this centralized study, which involved 163 institutions located in 43 states, we determined MICs for representatives of five antimicrobial classes: beta-lactams (penicillin, co-amoxiclav, cefuroxime, ceftriaxone), macrolides (azithromycin, clarithromycin), co-trimoxazole, glycopeptides (vancomycin) and fluoroquinolones (levofloxacin). In most S. pneumoniae isolates, all antimicrobials were to be found active, but amongst penicillin-resistant isolates (MICs > or = 2 mg/L), resistance to other beta-lactams, macrolides and co-trimoxazole was common. For vancomycin and levofloxacin, however, activity was not associated with penicillin resistance. The prevalence of penicillin-nonsusceptible (intermediate and resistant) pneumococci was highest in the South Atlantic (44%) and East South Central (43%) regions and lowest in the Mid-Atlantic (28%) and New England (28%) regions. Resistance to beta-lactams, macrolides and co-trimoxazole was more commonly found amongst respiratory isolates than blood isolates and in strains from patients < or = 12 years old than from older patients. beta-lactamase, which was detected in 33% of H. influenzae and 92% of M. catarrhalis strains, did not affect the activity of the beta-lactams under study other than ampicillin. Certain agents, such as vancomycin and the fluoroquinolones, remain highly active, and well-designed surveillance systems that monitor MIC distributions would be needed to detect a potential for reduced susceptibility. In addition, surveillance programmes should be designed to collect information about associated resistance as well as differences in prevalence associated with region, specimen source and patient age.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10590275     DOI: 10.1093/jac/44.6.749

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

1.  In vitro and In vivo activities of LB 10827, a new oral cephalosporin, against respiratory pathogens.

Authors:  K S Paek; M Y Kim; C S Lee; H Youn
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain.

Authors:  James A Karlowsky; Ian A Critchley; Renée S Blosser-Middleton; Elena A Karginova; Mark E Jones; Clyde Thornsberry; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Relationship between antibiotic resistance in Streptococcus pneumoniae and that in Haemophilus influenzae: evidence for common selective pressure.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian Critchley; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

5.  Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year.

Authors:  B D Gaynor; K A Holbrook; J P Whitcher; S O Holm; H C Jha; J S P Chaudhary; R C Bhatta; T Lietman
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

6.  Longitudinal assessment of antipneumococcal susceptibility in the United States.

Authors:  Mark E Jones; James A Karlowsky; Renée Blosser-Middleton; Ian A Critchley; Elena Karginova; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.

Authors:  M E Jones; A M Staples; I Critchley; C Thornsberry; P Heinze; H D Engler; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 8.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

9.  In vitro activities of broad-spectrum cephalosporins against nonmeningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations.

Authors:  Daniel F Sahm; Clyde Thornsberry; David C Mayfield; Mark E Jones; James A Karlowsky
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

10.  Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor.

Authors:  Juan-Carlos Galán; María-Isabel Morosini; María-Rosario Baquero; Milagro Reig; Fernando Baquero
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.